A2B adenosine receptor-mediated induction of IL-6 promotes CKD

Journal of the American Society of Nephrology

Volumn 22, Issue 5, 2011, Pages 890-901

  Dai, Yingbo ^a,b   Zhang, Weiru ^a,b   Wen, Jiaming ^a,b   Zhang, Yujin ^a   Kellems, Rodney E ^a   Xia, Yang ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE DEAMINASE; ANGIOTENSIN II; INTERLEUKIN 6; PEGADEMASE; PSB 1115; UNCLASSIFIED DRUG; COLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNILATERAL URETERAL OBSTRUCTION; URETER OBSTRUCTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHRONIC DISEASE; FIBROSIS; HUMAN; KIDNEY; KIDNEY DISEASE; MALE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADENOSINE DEAMINASE; ANGIOTENSIN II; ANIMALS; CHRONIC DISEASE; COLLAGEN; FIBROSIS; HUMANS; INTERLEUKIN-6; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION; URETERAL OBSTRUCTION;

EID: 79955574684     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010080890     Document Type: Article

References (51)

1. Kuroki A, Akizawa T: [Management of chronic kidney disease-preventing the progression of renal disease]. Nippon Rinsho 66: 1735-1740, 2008
2. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008
3. Strutz F, Zeisberg M: Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 17: 2992-2998, 2006
4. Zeisberg M, Strutz F, Muller GA: Renal fibrosis: An update. Curr Opin Nephrol Hypertens 10: 315-320, 2001
5. Bidani AK, Griffin KA: Pathophysiology of hypertensive renal damage: Implications for therapy. Hypertension 44: 595-601, 2004
6. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34, 2000
7. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics. Kidney Int 74: 867-872, 2008
8. Nangaku M, Fujita T: Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 31: 175-184, 2008
9. Fredholm BB: Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14: 1315-1323, 2007
10. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, Colgan SP: Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: Coordination by extracellular nucleotide metabolism. Blood 104: 3986-3992, 2004
11. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, Xia Y: Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118: 1491-1501, 2008
12. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB: Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 4: 346-369, 1992
13. Schubert P, Rudolphi KA, Fredholm BB, Nakamura Y: Modulation of nerve and glial function by adenosine: Rrole in the development of ischemic damage. Int J Biochem 26: 1227-1236, 1994
14. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Elzschig HK: The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 5: e137, 2008
15. Lasley RD, Rhee JW, Van Wylen DG, Mentzer RM Jr: Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart. J Molec Cell Cardiol 22: 39-47, 1990
16. Fishman P, Bar-Yehuda S, Farbstein T, Barer F, Ohana G: Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 adenosine receptors. J Cell Physiol 183: 393-398, 2000
17. Linden J: Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67: 1385-1387, 2005
18. Lu B, Rajakumar SV, Robson SC, Lee EK, Crikis S, d'Apice AJ, Cowan PJ, Dwyer KM: The impact of purinergic signaling on renal ischemiareperfusion injury. Transplantation 86: 1707-1712, 2008
19. Hatfield S, Belikoff B, Lukashev D, Sitkovsky M, Ohta A: The antihypoxia- adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. J Leukoc Biol 86: 545-548, 2009
20. Vallon V, Muhlbauer B, Osswald H: Adenosine and kidney function. Physiol Rev 86: 901-940, 2006
21. Hershfield MS: PEG-ADA replacement therapy for adenosine deaminase deficiency: An update after 8.5 years. Clin Immunol Immunopathol 76: S228-S232, 1995
22. Hershfield MS: PEG-ADA: An alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 5: 107-112, 1995
23. Hershfield MS: New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35: 25-30, 2005
24. Wolf G: Angiotensin II is involved in the progression of renal disease: Importance of non-hemodynamic mechanisms. Nephrologie 19: 451-456, 1998
25. Guo G, et al: Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol 280: F777-F785, 2001
26. Klahr S, Morrissey JJ: The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 18: 622-632, 1998
27. Klahr S: Mechanisms of progression of chronic renal damage. J Nephrol 12[Suppl 2]: S53-S62, 1999
28. Carrero JJ, Park SH, Axelsson J, Lindholm B, Stenvinkel P: Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: A dreadful triad. Semin Dialysis 22: 381-386, 2009
29. Pachaly MA, do Nascimento MM, Sulliman ME, Hayashi SY, Rielia MC, Manfro RC, Stenvinkel P, Lindholm B: Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. Blood Purif 26: 204-210, 2008
30. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia- the good, the bad, and the ugly. Kidney Int 67: 1216-1233, 2005
31. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17: 1684-1688, 2002
32. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR: Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116: 2173-2182, 2006
33. Wen J, Jiang X, Dai Y, Zhang Y, Tang Y, Sun H, Mi T, Phatarpekar PV, Kellems RE, Blackburn MR, Xia Y: Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J 24: 740-749, 2010
34. Blackburn MR, Datta SK, Kellems RE: Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273: 5093-5100, 1998
35. Blackburn MR, Kellems RE: Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 86: 1-41, 2005
36. Ratech H, Greco MA, Gallo G, Rimoin DL, Kamino H, Hirschhorn R: Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol 120: 157-169, 1985
37. Covic A, Gusbeth-Tatomir P: The role of the renin-angiotensin-aldosterone system in renal artery stenosis, renovascular hypertension, and ischemic nephropathy: Diagnostic implications. Prog Cardiovasc Dis 52: 204-208, 2009
38. Mori T, Cowley AW Jr, Ito S: Molecular mechanisms and therapeutic strategies of chronic renal injury: Physiological role of angiotensin IIinduced oxidative stress in renal medulla. J Pharmacol Sci 100: 2-8, 2006
39. Steinhausen M, Endlich K, Wiegman DL: Glomerular blood flow. Kidney Int 38: 769-784, 1990
40. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP: Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198: 783-796, 2003
41. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP: HIFdependent induction of adenosine A2B receptor in hypoxia. FASEB J 20: 2242-2250, 2006
42. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Elzschig HK: Hypoxia-inducible factordependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 10: 195-202, 2009
43. Blackburn MR, Datta SK, Wakamiya M, Vartabedian BS, Kellems RE: Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J Biol Chem 271: 15203-15210, 1996
44. Chen JF, Huang Z, Ma J, Zhu J, Moratalia R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA: A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 9192-9200, 1999
45. Chunn JL, Mohsenin A, Young HW, Lee CG, Elias JA, Kellems RE, Balckburn MR: Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations. Am J Physiol Lung Cell Mol Physiol 290: L579-L587, 2006
46. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Balackburn MR: Adenosine- dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 175: 1937-1946, 2005
47. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR: Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J Immunol 167: 4676-4685, 2001
48. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 121: 436-444, 2010
49. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 14: 855-862, 2008
50. Irani RA, Zhang Y, Blackwell SC, Zhou CC, Ramin SM, Kellems RE, Xia Y: The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J Exp Med 206: 2809-2822, 2009
51. Irani RA, Zhang Y, Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y: Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor- alpha signaling. Hypertension 55: 1246-1253, 2010